

# Erica L Woodahl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2592513/publications.pdf>

Version: 2024-02-01

27  
papers

877  
citations

471061

17  
h-index

552369

26  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1299  
citing authors

#	ARTICLE	IF	CITATIONS
1	Keeping pace with <i>CYP2D6</i> haplotype discovery: innovative methods to assign function. <i>Pharmacogenomics</i> , 2022, 23, 255-262.	0.6	2
2	Advancing equity in the promise of pharmacogenomics. , 2022, , 85-106.		1
3	PharmVar GeneFocus: <i>CYP2C19</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 352-366.	2.3	72
4	PharmVar GeneFocus: <i>CYP2C9</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 662-676.	2.3	34
5	Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting <i>CYP3A4*1G</i> allele function. <i>Clinical and Translational Science</i> , 2021, 14, 1292-1302.	1.5	7
6	Interrogation of <i>CYP2D6</i> Structural Variant Alleles Improves the Correlation Between <i>CYP2D6</i> Genotype and <i>CYP2D6</i> -Mediated Metabolic Activity. <i>Clinical and Translational Science</i> , 2020, 13, 147-156.	1.5	42
7	Food dyes as P-glycoprotein modulators. <i>Food and Chemical Toxicology</i> , 2020, 146, 111785.	1.8	4
8	Transfer learning enables prediction of <i>CYP2D6</i> haplotype function. <i>PLoS Computational Biology</i> , 2020, 16, e1008399.	1.5	32
9	Stargazer: a software tool for calling star alleles from next-generation sequencing data using <i>CYP2D6</i> as a model. <i>Genetics in Medicine</i> , 2019, 21, 361-372.	1.1	86
10	Democratizing Precision Medicine Through Community Engagement. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 488-490.	2.3	21
11	Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People. <i>Clinical and Translational Science</i> , 2018, 11, 312-321.	1.5	34
12	P450 Pharmacogenetics in Indigenous North American Populations. <i>Journal of Personalized Medicine</i> , 2018, 8, 9.	1.1	22
13	Partnership with the Confederated Salish and Kootenai Tribes: Establishing an Advisory Committee for Pharmacogenetic Research. <i>Progress in Community Health Partnerships: Research, Education, and Action</i> , 2016, 10, 173-183.	0.2	14
14	Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas. <i>Pharmacogenomics</i> , 2015, 16, 227-237.	0.6	23
15	Gentamicin-induced ototoxicity and nephrotoxicity vary with circadian time of treatment and entail separate mechanisms. <i>Chronobiology International</i> , 2015, 32, 1223-1232.	0.9	33
16	P-Glycoprotein Transport of Neurotoxic Pesticides. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 355, 99-107.	1.3	22
17	Pharmacogenetic research in partnership with American Indian and Alaska Native communities. <i>Pharmacogenomics</i> , 2014, 15, 1235-1241.	0.6	37
18	Absence of P-Glycoprotein Transport in the Pharmacokinetics and Toxicity of the Herbicide Paraquat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 336-345.	1.3	17

#	ARTICLE	IF	CITATIONS
19	Pharmacogenetics in American Indian populations. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 403-414.	0.7	54
20	A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 263-272.	1.1	17
21	A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 391-401.	1.1	19
22	Intracellular disposition of fludarabine triphosphate in human natural killer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 959-964.	1.1	7
23	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 183-188.	1.1	30
24	Imatinib inhibition of fludarabine uptake in T-lymphocytes. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 735-739.	1.1	15
25	MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. <i>Aids</i> , 2005, 19, 1617-1625.	1.0	47
26	(Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function. <i>Current Drug Metabolism</i> , 2004, 5, 11-19.	0.7	102
27	Multidrug Resistance Gene G1199A Polymorphism Alters Efflux Transport Activity of P-Glycoprotein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 1199-1207.	1.3	74